Title

Dietary Supplements for the Treatment of Angelman Syndrome
Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome
  • Phase

    N/A
  • Study Type

    Interventional
  • Study Participants

    90
Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.
AS is a neurologic disorder that may cause developmental delay, mental retardation, severe speech impairment, seizures, small head size, and problems with movement and balance in young children. AS is caused by a missing or incomplete chromosome 15 that is inherited from the mother. Diagnosis of AS is usually made between three and seven years of age, when the characteristic behaviors and features of the disease become most evident. Prior to AS diagnosis, the symptoms may be mistaken for cerebral palsy or autism. Physical, occupational, and speech therapy, communication skills development, and behavior modification help to improve the quality of life of these children, but other treatments are needed.

In a previous study, decreased DNA methylation, which is a type of chemical change in DNA, was observed in an individual with AS; this condition may be a primary cause of AS. It is hypothesized that promoting increased DNA methylation might reduce the severity of AS symptoms. Betaine, creatine, Metafolin, and vitamin B12 are compounds normally found in the body that are involved in the DNA methylation pathway. Increasing the concentrations of these compounds in the body may enhance DNA methylation. This study will evaluate the efficacy of four dietary supplements in treating the symptoms of AS.

This study will last 12 months. Study visits will occur at study entry and Month 12. A selected group of participants, those who meet the diagnostic criteria for autism, will also be evaluated at Month 6. At study visits, participants will undergo an electroencephalogram (EEG). Medical history, physical exam, neurological exams, and developmental assessments will also be performed. Urine and blood collection, including tests to determine the blood levels of the dietary supplements, will occur at study entry and Months 6 and 12. Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for the duration of the study. Parents will be asked to complete a questionnaire at each visit to report their child's behavior while taking the dietary supplements. Parents will also be contacted by phone periodically to assess changes and/or progress in their children.
Study Started
Jul 31
2006
Primary Completion
Feb 28
2010
Study Completion
Feb 28
2010
Results Posted
Sep 24
2012
Estimate
Last Update
Sep 24
2012
Estimate

Drug Betaine

100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses

Drug Creatine

200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses

Drug Metafolin

0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses

Drug Vitamin B12

1 mg by mouth per day for all weights and ages

1 Experimental

Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.

Criteria

Inclusion Criteria:

Diagnosis of AS
In stable condition with relatively good control of seizures
Willing to comply with treatment, study visit schedule, and study assessments
Willing to take oral or G-tube medication
Willing to be contacted monthly during the course of the study
Parent or guardian willing to provide informed consent

Exclusion Criteria:

History of liver or kidney disease
Currently being treated for a serious acute illness
Known hypersensitivity to any of the study drugs
Received high-dose folate drug treatment in the 12 months prior to study entry
Other significant medical problems, including those involving the liver, kidney, or heart
Other comorbidities, genetic disorders, or extreme prematurity; children with autism are not excluded

Summary

Metafolin, Betaine, Creatine, B12 Treatment

All Events

Event Type Organ System Event Term Metafolin, Betaine, Creatine, B12 Treatment

Average Change in Functioning in Specific Areas of Development, Including Speech and Communications Skills, Cognitive Abilities and Daily Living Skills

Primary: Bayley Scales of Infant Development measures Mental Developmental Index standard scores 0 (least skilled) - 100 (most skilled) Psychomotor Developmental Index standard scores 0 (least skilled - 10 (most skilled) Vineland Adaptive Behavior Scales (VABS), Communication standard scores 0 (least skilled) - 100 (most skilled) Daily Living Skills standard scores 0 (least skilled) - 100 (most skilled) Socialization standard scores 0 (least skilled) - 100 (most skilled) Motor Skills standard scores 0 (least skilled) - 100 (most skilled) Preschool Language Scale (PLS), Auditory Comprehension 0 (least skilled) - 100 (most skilled) Expressive Communication 0 (least skilled) - 100 (most skilled)

Treatment (Metafolin/Creatine/Betaine/B12)

Bayley Scales Mental Developmental Index

5.7
units on a scale (Mean)
Standard Deviation: 7.8

Bayley Scales Psychomotor Developmental Index

4.7
units on a scale (Mean)
Standard Deviation: 8.6

PLS Auditory Comprehension

2.0
units on a scale (Mean)
Standard Deviation: 10.8

PLS Expressive Communication

5.5
units on a scale (Mean)
Standard Deviation: 9.6

VABS Communication

5.8
units on a scale (Mean)
Standard Deviation: 8.3

VABS Daily Living Skills

3.7
units on a scale (Mean)
Standard Deviation: 7.9

VABS Motor Skills

2.0
units on a scale (Mean)
Standard Deviation: 6.1

VABS Socialization

4.7
units on a scale (Mean)
Standard Deviation: 5.2

Change in Levels of Betaine, Creatine, Dimethylglycine, Guanidinoacetate, Homocysteine, and Methionine.

Treatment (Metafolin/Creatine/Betain/B12)

Betaine

206.9
mmol/L (Mean)
Standard Deviation: 224.5

Creatine

83.3
mmol/L (Mean)
Standard Deviation: 165.9

Dimethylglycine

93.7
mmol/L (Mean)
Standard Deviation: 129

Guanidinoacetate

0.11
mmol/L (Mean)
Standard Deviation: 0.34

Homocysteine

2.3
mmol/L (Mean)
Standard Deviation: 2.1

Methionine

5.5
mmol/L (Mean)
Standard Deviation: 12.1

Change in RBC Folate

Treatment (Metafolin/Creatine/Betaine/B12)

77.0
ng/mL (Mean)
Standard Deviation: 267

Age Continuous

2.9
years (Mean)
Standard Deviation: 1.2

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Metafolin, Betaine, Creatine, B12 Treatment

Drop/Withdrawal Reasons

Metafolin, Betaine, Creatine, B12 Treatment